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tracaomatis and CMamydia pneumoniae
re pathogens with an extremely narrow host
range (humans) and are limited to existence within
the confines of a membrane-bound vesicle con-
tained in the cytoplasm of susceptible host cells.
In the case of C. tracomatis, with the notable excep-
tion of the lymphogranuloma venereum biovar,
active growth and progression to a productive
infection, with generation of infectious forms (ele-
mentary bodies, EB), appears to be restricted to
epithelial cells lining either ocular (conjunctiva) or
genital (urethra in males, endocervix to fallopian
tubes in females) mucosal surfaces, although spread
to deeper tissue and in the case in Reiter’s disease,
synovium, is possible. In the case of (7. pneumoniae,
a broader host cell range exists that includes respira-
tory epithelial cells, alveolar macrophages and
perhaps monocytes and cells of the vascular endo-
thelium.
Long term sequelae ofacute human 6". trachomatis
and 6".pneumoniaeinfections include chronic local tis-
sue damage that may reflect persistent or occult in-
fection, alone or superimposed upon reinfection that
lead to immunologic consequences which are di-
rectly associated with disease manifestations.
Chronic aspects of chlamydial infections include
scarring trachoma, damage to fallopian tubes for 6".
tracomatis and possibly development of atheroscle-
rotic lesions for C.pneumoniae. At present it is unclear
what, ifany, role persistent, viable but metabolically
quiescent chlamydiae play in the more chronic as-
pects ofhuman chlamydial infections, but extensive
cell culture studies have provided evidence that
chlamydial persistence in the form of aberrently
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growing organisms can be induced by a variety ofex-
ternal stimuli and more recently in vivo data has in
large measure supported claims made based on cell
culture models of persistence.
CELL CULTURE MODELS OF PERSISTENCE
Chlamydia normally proceed through an orderly al-
ternation of functionally and morphologically dis-
tinct developmental forms that begin and end with
the production of metabolically inactive, infectious
EB, interspersed with the metabolically active, but
non-infectious intracellular form called the reticu-
late body (RB). Productive infections necessarily
begin and end with EB, but a variety of cell culture
manipulations can be introduced that prevent or
delay RB from differentiating to EB. The result of
these manipulations extend the length of time non-
infectious RB remain within intracellular cyto-
plasmic vesicles and often this extended period of
non-productive growth is associated with the devel-
opment of morphologically abnormal (often very
large) intracellular forms of the organism. Variations
of these alternative growth options have been stud-
ied in the context of antibiotic treatments (penicil-
lin, some quinalones), nutrient deprivation (espe-
cially amino acids), cytokine-mediated activation of
host cells (also resulting in nutrient deprivation,
especially tryptophan) and a variety of other stress-
ful changes in the environment, including heat
shock. Collectively, these various studies that in-
volve production of chronic cell culture models of
chlamydial growth have been referred to as persis-
tence and have been the subject of several recent
review articles.6’7
Persistence is a term that was developed to dis-
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tinguish the usual mode of intracellular chlamydial
development from the morphologically altered in-
tracellular forms that often arise under conditions
when extended RB development occurs. Clearly,
the latter mode of intracellular existence should not
be considered latency since a metabolically active
form of the organism is continuously present, even
though infectivity is not achieved since EB do not
emerge in a timely manner. Cell culture persistence
also is not a dead-end pathway, since productive
infections can resume after the persistence-induc-
ing conditions have been alleviated.
An interesting feature of cell culture persistence
that has been associated with cytokine-mediated
activation of infected host cells is a change in the
pattern of protein expression that reflects a stress-
related response and a decline in the expression of
constitutive and developmentally-regulated enve-
lope proteins. It has been suggested6’7 that if similar
changes in protein expression could be documented
in vivo in association with chronic chlamydial dis-
ease, then this could help explain disease pathogen-
esis since chlamydial stress-response proteins have
been implicated as mediators of untoward immune
reactivity in animal models of chlamydial in-
fections.
PERSISTENCE IN VlVO
Documentation of the details associated with per-
sistent growth have remained restricted to cell cul-
ture models. However several in vivo investigations
have provided inferential support for the hypothesis
that persistent chlamydiae contribute to long term
sequelae of chlamydial disease in vivo. Certain fea-
tures associated with in vivo growth would be con-
sistent with growth options that include some form
of persistence. These include the presence of ab-
normally large intracellular forms of the organism
in diseased tissue, evidence for chlamydial nucleic
acid in the absence of demonstrable culturable
forms, immunologic evidence for heightened reac-
tivity to stress response proteins and the continuous
presence of chlamydial antigens in the absence of
re-infections.
To one degree or another, at least some of these
conditions have been met for several chronic chla-
mydial diseases. The most likely clinical situations
involving the presence of persistent C. trachomatis
include, chronic upper genital tract disease in
women (chlamydial genomes identified in submu-
cosal tissue in the absence of infectious organisms)
and Reiter’s disease (persistently infected synovial
cells perhaps expressing stress response gene tran-
scripts). The most likely clinical situations involving
the presence of persistent C. pneumoniae include
atherosclerotic lesions (PCR and RT-PRC evidence
for genomes and transcripts) and some forms of
adult onset asthma (chronic disease with serologic
evidence for C.pneumoniae). Work using actual clini-
cal disease to verify the involvement of persistent
chlamydiae in the disease process have thus far
been limited in scope and far from conclusive. Suffi-
cient data has been generated, however, to warrant
more extensive studies to support or refute the pres-
ence of occult chlamydiae as a mediator of patho-
genesis.
PROSPECTUS
Study of clinical material from various human chla-
mydial syndromes for evidence of persistent chla-
mydiae will eventually provide a definitive answer
to the question of chlamydial persistence. Other
work also will be of value in better defining alterna-
tive modes of intracellular chlamydial growth as
these relate to the disease process. Use of appro-
priate animal models including the C. trachomatis
mouse pneumonitis model for chlamydial upper
genital tract disease in female mice and the ApoE-
deficient mouse model for the study of cardiac
involvement for C. pneumoniae
1 will be instructive.
In addition, cell culture models that more accurately
reflect in vivo conditions should help to provide
details concerning the conditions under which chla-
mydiae are likely to enter persistent growth states.
For example, in recent studies using polarized hu-
man genital epithelial cells, we have found that
persistent C. trachomatis growth can be established
and maintained much much more readily than with
the more standard conditons of cell culture (Kane
and Byrne, unpublished).
Application of each of these broad areas of re-
search (evaluation of clinical samples, animal mod-
els and more appropriate mimicks of in vivo condi-
tions) will combine to provide a clear answer to the
question of whether persistent growth is an in vivo
reality or a cell culture artifact.
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